Advertisement

ADVERTISEMENT

multiple myeloma

Conference Coverage
Real-world Outcomes of ASCT in Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma
12/10/2022

Craig Ostroff

Craig Ostroff
Julie Cote, MD, and colleagues discuss real-world outcomes of patients treated with autologous stem cell transplant as part of their initial multiple myeloma therapy during their presentation at the 64th ASH Annual Meeting and Exposition.
Julie Cote, MD, and colleagues discuss real-world outcomes of patients treated with autologous stem cell transplant as part of their initial multiple myeloma therapy during their presentation at the 64th ASH Annual Meeting and Exposition.
Julie Cote, MD, and colleagues...
12/10/2022
Journal of Clinical Pathways
Dr Fonseca
Videos
Dr Fonseca Highlights Phase 2 GRIFFIN Study Results for Newly Diagnosed MM
12/13/2021
Rafael Fonseca, MD, Mayo Clinic, discusses new results from the Phase 2 GRIFFIN study of daratumumab, as part of a quadruplet regimen in newly diagnosed multiple myeloma, presented at the 2021 ASH Annual Meeting.
Rafael Fonseca, MD, Mayo Clinic, discusses new results from the Phase 2 GRIFFIN study of daratumumab, as part of a quadruplet regimen in newly diagnosed multiple myeloma, presented at the 2021 ASH Annual Meeting.
Rafael Fonseca, MD, Mayo Clinic,...
12/13/2021
Oncology
NCCN Updates Clinical Practice Guideline for Multiple Myeloma
NCCN Updates Clinical Practice Guideline for Multiple Myeloma
03/15/2021

Janelle Bradley

Janelle Bradley
The National Comprehensive Cancer Network released an update to its clinical practice guideline for multiple myeloma.
The National Comprehensive Cancer Network released an update to its clinical practice guideline for multiple myeloma.
The National Comprehensive...
03/15/2021
Journal of Clinical Pathways
News
DRd Improves PROs Compared With Rd for Newly Diagnosed MM
02/01/2021
02/01/2021
Journal of Clinical Pathways
FDA Approves Selinexor in Combination With Bortezomib and Dexamethasone for MM
FDA Alerts
FDA Approves Selinexor in Combination With Bortezomib and Dexamethasone for MM
12/18/2020
12/18/2020
Journal of Clinical Pathways
News
Risk Score to Predict Early Infection in Patients With Multiple Myeloma
06/26/2020
A post-hoc analysis presented at the European Hematology Association (EHA) Annual Meeting (June 11-21, 2020) led to a new risk prediction score for early severe infection in patients with multiple myeloma. Many...
A post-hoc analysis presented at the European Hematology Association (EHA) Annual Meeting (June 11-21, 2020) led to a new risk prediction score for early severe infection in patients with multiple myeloma. Many...
A...
06/26/2020
Journal of Clinical Pathways
News
Isatuximab Combination Effective in Myeloma and Soft-Tissue Plasmacytomas
06/22/2020
Isatuximab plus pomalidomide and dexamethasone (Isa-Pd) significantly prolongs progression-free survival (PFS) and improves overall response rate (ORR) compared with pomalidomide plus dexamethasone alone (Pd) in...
Isatuximab plus pomalidomide and dexamethasone (Isa-Pd) significantly prolongs progression-free survival (PFS) and improves overall response rate (ORR) compared with pomalidomide plus dexamethasone alone (Pd) in...
...
06/22/2020
Journal of Clinical Pathways
News
HRQoL of Patients With Heavily Pretreated or Renally Impaired Multiple Myeloma
06/18/2020
Isatuximab in combination with pomalidomide and dexamethasone may provide an effective treatment option in relapsed or refractory multiple myeloma, including difficult-to-treat subgroups of these patients, and may...
Isatuximab in combination with pomalidomide and dexamethasone may provide an effective treatment option in relapsed or refractory multiple myeloma, including difficult-to-treat subgroups of these patients, and may...
...
06/18/2020
Journal of Clinical Pathways
Feature
Multidisciplinary Management of Multiple Myeloma in Older Adults
08/17/2017
Nader Tavakoli, MD, CMD, FAAFP
Sidrah Khan, MD
Shelby Knowles, MD
Richard Stefanacci, DO, MGH, MBA, AGSF, CMD
Abstract: Multiple myeloma (MM) is a progressive and fatal disease, primarily affecting men aged 66 years or older. Because MM is primarily a disease of the elderly, it is incumbent on geriatricians and primary care...
Abstract: Multiple myeloma (MM) is a progressive and fatal disease, primarily affecting men aged 66 years or older. Because MM is primarily a disease of the elderly, it is incumbent on geriatricians and primary care...
...
08/17/2017
Journal of Clinical Pathways
Author Insights
Cost-Effective Alternative Identified for Autologous Stem Cell Mobilization in Multiple Myeloma
08/14/2017
Pavan Bhamidipati, MBBS, MD
In a randomized, open-label study, we discovered that tbo-filgrastim (Granix) can be used in the place of filgrastim (Neupogen) for autologous stem cell mobilization for multiple myeloma and non-Hodgkin’s lymphoma...
In a randomized, open-label study, we discovered that tbo-filgrastim (Granix) can be used in the place of filgrastim (Neupogen) for autologous stem cell mobilization for multiple myeloma and non-Hodgkin’s lymphoma...
In a...
08/14/2017
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

November 23 ⁠–⁠ November 24
December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
AIBD
December 9 ⁠–⁠ December 11
December 9 ⁠–⁠ December 11
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
December 14 ⁠–⁠ December 15
February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use